Motohiro Tamiya

7PUBLICATIONS
35CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 25, 2025
Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1-Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study.

Kohei Shitara, Motohiro Tamiya, Kyoichi Okishio

|Jan 05, 2024
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort.

Makoto Nishio, Shuji Murakami, Hisato Kawakami

|Jan 28, 2022
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002.

Motohiro Tamiya, Kei Fujikawa, Hidekazu Suzuki

|Feb 05, 2021
Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion.

Motohiro Tamiya, Akihiro Tamiya, Hidekazu Suzuki

|Jun 20, 2020
Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab.

Motohiro Tamiya, Kei Kunimasa, Kazumi Nishino

|Dec 01, 2019
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.

Hayato Kawachi, Motohiro Tamiya, Akihiro Tamiya

Pageof 2

Frequent Collaborators

2 joint publications

Kyoichi Okishio

2 joint publications

Hiroki Izumi

1 joint publications

Makoto Nishio

1 joint publications

Shuji Murakami